Cancer of Unknown Primary
8
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Agnostic Therapy in Rare Solid Tumors
Enabling Genomic Testing in Cancer of Unknown Primary
Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary
Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary